The Growth of Simian Virus 40 (SV40) Host Range/Adenovirus Helper Function Mutants in an African Green Monkey Cell Line that Constitutively Expresses the SV40 Agnoprotein. by Stacy, Terryl P et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
7-1990
The Growth of Simian Virus 40 (SV40) Host
Range/Adenovirus Helper Function Mutants in an
African Green Monkey Cell Line that
Constitutively Expresses the SV40 Agnoprotein.
Terryl P. Stacy
Dartmouth College
Michele Chamberlain
Dartmouth College
Susan Carswell
University of Pennsylvania
Charles N. Cole
Dartmouth College
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medical Biochemistry Commons, Medical Genetics Commons, Medical
Microbiology Commons, and the Virology Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Stacy, Terryl P.; Chamberlain, Michele; Carswell, Susan; and Cole, Charles N., "The Growth of Simian Virus 40 (SV40) Host Range/
Adenovirus Helper Function Mutants in an African Green Monkey Cell Line that Constitutively Expresses the SV40 Agnoprotein."
(1990). Open Dartmouth: Faculty Open Access Articles. 1177.
https://digitalcommons.dartmouth.edu/facoa/1177
JOURNAL OF VIROLOGY, JUlY 1990, p. 3522-3526
0022-538X/90/073522-05$02.00/0
Copyright C 1990, American Society for Microbiology
The Growth of Simian Virus 40 (SV40) Host Range/Adenovirus
Helper Function Mutants in an African Green Monkey Cell Line
That Constitutively Expresses the SV40 Agnoprotein
TERRYL P. STACY,1'2 MICHELE CHAMBERLAIN,"2 SUSAN CARSWELL,3 AND CHARLES N. COLE'.2*
Department of Biochemistry, Dartmouth Medical School,1 and The Molecular Genetics Center, Dartmouth College,2
Hanover, New Hampshire 03756, and Department of Microbiology, University ofPennsylvania School of Medicine,
Philadelphia, Pennsylvania 191043
Received 20 February 1990/Accepted 13 March 1990
The simian virus 40 T-antigen carboxy-terminal mutants, dlA2459 and dlA2475, are cell line and
temperature dependent for growth and plaque formation in monkey kidney cells. Although these mutants did
form plaques on BSC-1 cells at 37°C, they were about fivefold less efficient for plaque formation than wild-type
simian virus 40. These mutants did not grow in CV-1 cells and did not synthesize agnoprotein in those cells.
CV-1 cells which constitutively express the agnoprotein were permissive for mutant plaque formation.
However, late mRNAs, virion proteins, and progeny virion yields did not accumulate to wild-type levels during
mutant infection of the agnoprotein-producing cells.
Expression of the simian virus 40 (SV40) large tumor (T)
anitgen is essential throughout the infection cycle in permis-
sive monkey kidney cells (for a review, see reference 31). T
antigen is required for viral DNA replication (6, 18, 26, 28),
autoregulation of SV40 early transcription (1, 29), and trans-
activation of the SV40 late promoter (3, 15, 16). Among the
biochemical activities identified with T antigen are ATPase
(7, 12), helicase (25), and specific binding to the SV40 origin
of DNA replication (14, 22, 30). These activities have been
mapped to regions of the T-antigen molecule extending from
approximately amino acid 130 to 600 and are all required on
the same T-antigen monomer for viral DNA replication (10,
32).
We have shown that the extreme carboxy terminus of
SV40 T antigen mediates the host range/adenovirus helper
function (hrlhf) (9, 24). Human adenoviruses produce very
low progeny yields in most monkey kidney cell lines, but the
block to productive infection of monkey cells can be over-
come by SV40 T antigen (for a review, see reference 17). The
adenovirus helper function activity of T antigen is contained
within the carboxy-terminal 34 amino acids of T antigen (8,
21). Deletion mutants dlA2459 and dIA2475, which lack the
carboxy-terminal 35 and 28 amino acids, respectively, of T
antigen, were absolutely defective in providing helper func-
tion to human adenovirus in CV-1 cells, an African green
monkey kidney cell line. These mutants also produced
extremely low SV40 viral yields and were unable to form
plaques in CV-1 cells at 37°C. The hrlhf mutants were more
cold sensitive than wild-type SV40 for plaque formation and
progeny yield in all cell lines tested. dlA2459 and dIA2475
were able to form plaques and produced higher viral yields
on BSC-1 and Vero African green monkey kidney cells.
Interestingly, human adenoviruses also grow productively in
Vero cells, but not in other monkey kidney cell lines (11).
These observations suggest that the adenovirus helper func-
tion of T antigen is also required by SV40 for productive
infection in CV-1 cells. Complementation analysis has
shown that the hrlhfmutants can form plaques in CV-1 cells
when the carboxy terminus of T antigen is provided in trans,
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even when that region of T antigen is fused to the SV40
capsid protein, VP1 (34). The hrlhf activity of T antigen is,
therefore, separable from the rest of T antigen.
Although Vero cells were the most permissive for the
growth of SV40 hrlhfmutants, these cells do not survive well
under plaque assay conditions. BSC-1 cells, which were
more permissive for hrlhf mutant viral progeny production
than CV-1 cells, were routinely used in plaque assays to
determine titers of mutant viral stocks and measure mutant
viral yields. Plaque sizes are relatively insensitive to the
amount of infectious progeny produced within a single cell;
for example, plaque size and rate of plaque enlargement are
very similar for yields in the range of 500 to 5,000 PFU per
cell. With smaller burst sizes, plaques will be smaller and
enlarge more slowly, and at still lower burst sizes, plaques
will not form at all. In addition, there probably exists a
narrow range of burst sizes which result in plaque formation
in only a fraction of infected cells. Since hrlhfmutant yields
were both cell line and temperature dependent, and since
plaques formed by these mutants in BSC-1 cells were smaller
than wild-type plaques, it was possible that not all BSC-1
cells infected by the hrlhf mutants would give rise to a
plaque. If this were the case, measuring mutant viral yields
and virus stock titers by plaque assay would underestimate
their true values.
We therefore performed an infectious-center assay. Con-
fluent monolayers of BSC-1 cells were infected with wild-
type SV40 or dlA2475 at a multiplicity of infection of 5 to
infect all of the cells. Eighteen hours later, the infected cells
were removed from the plates, counted, and serially diluted
into suspensions of uninfected BSC-1 cells. The mixed cell
suspensions were replated, incubated in cell culture medium
for 4 h to settle the cells, and then overlaid with medium
containing agar, as for plaque assays (32). After 8 days,
duplicate samples were stained with neutral red and plaques
were counted.
The results of this infectious-center assay are shown in
Table 1. BSC-1 cells infected with wild-type SV40 produced
plaques with 80 to 100% efficiency, while only 15 to 20% of
dlA2475-infected cells resulted in visible plaques. Under
conditions where the wild-type virus appeared least efficient,
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TABLE 1. Comparison of the ability of wild-type SV40
and dlA2475 to produce plaques on BSC-1 cells
in an infectious-center assay
(no. of infected No. of plaques Efficiency of
cells plated) produceda plaque formationb
Wild type
400 TMTCC NDd
200 TMTC ND
100 50,70 0.6
50 36,45 0.81
25 25,20 0.89
12.5 19,13 1.20
dlA2475
400 55,55 0.14
200 22,28 0.13
100 25,15 0.20
50 13,10 0.23
25 3,5 0.16
12.5 2,2 0.16
a Maximum numbers of plaques formed on each of duplicate plates.
b Calculated by dividing the average number of plaques on each set of
duplicate plates by the number of infected cells plated.
c TMTC, Too many to count.
d ND, Not determined.
e.g., at 100 infected cells plated, the actual efficiency was
probably higher, since that many wild-type plaques would
overlap on a 60-mm plate. The inefficiency of plaque forma-
tion after infection by mutant virus suggested that there is
indeed a threshold in burst size, below which the number of
surrounding cells that become infected during the plaque
assay is insufficient to form a plaque before the death of the
cell monolayer. The hrlhf mutant plaques on BSC-1 cells
always appeared 2 or more days later and were significantly
smaller and more difficult to detect than wild-type plaques.
These observations also suggest a smaller burst size. Since
only 15 to 20% of mutant-infected cells gave rise to a plaque
in this infectious-center assay, titers of mutant virus stocks
obtained by plaque assay on BSC-1 cells underestimated the
true yield of infectious virions by a factor of 5 to 6.
Although the results obtained in this experiment could be
explained by inefficient adsorption, penetration, or uncoat-
ing, we believe this is unlikely for the following reasons.
Previous work has shown that similar amounts of viral DNA
are made in mutant- and wild-type-infected cells (24, 34).
This indicates that the events before DNA replication occur
normally in mutant-infected cells, regardless of whether the
cells support mutant plaque formation (BSC-1 cells) or not
(CV-1 cells). We concluded that the block to productive
infection in CV-1 cells involves late events in the lytic cycle
(24, 33). Both late mRNA and the major viral capsid protein,
VP1, accumulate to substantially lower levels in mutant
infections of CV-1 cells than in wild-type SV40 infections.
Also, the agnoprotein encoded in the SV40 late mRNA
leader is detectable in wild-type infections of CV-1 cells but
not in hr/hf mutant infections (24).
Mutant infection of CV-1 cells also results in an altered
pattern of late mRNA start site usage. Primer extension data
showed that the major late mRNA start site at SV40 nucle-
otide 325 was in fact the major site in wild-type-infected
CV-1 cells. However, most late messages found in mutant
infections initiate downstream from the agnoprotein transla-
tion initiation codon at nucleotide 335 and thus cannot
encode the agnoprotein (24). The agnoprotein has not been
detected in SV40 virions. It accumulates in SV40-infected
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FIG. 1. Mutant and wild-type plaque formation on CV-1, CV-1
Neo, and CV-1 Agl8 cells. Cell monolayers were mock infected or
infected with wild-type SV40 (wt) or dlA2475 as for plaque assays.
Plaques were visualized and stained 10 days after infection.
cells at late times in the lytic cycle and is thought to play a
role either in transport of VP1 to the nucleus or in virion
assembly (2, 4, 20, 23). The agnoprotein is not essential to
SV40 growth, because mutants which do not synthesize this
protein have a small plaque phenotype but are still viable
(13, 19, 27). Since the hrlhf mutants do not synthesize
detectable levels of the agnoprotein, we investigated
whether the agnoprotein supplied in trans could complement
the SV40 growth defect in CV-1 cells caused by deletion of
the carboxy terminus of T antigen.
The results of a plaque assay performed with wild-type
SV40 and dlA2475 in the CV-1 Agl8 cell line, which are
CV-1 cells that have been stably transformed with the DNA
encoding the agnoprotein and which constitutively express
this protein (5), are shown in Fig. 1. For comparison, the
abilities of wild-type and mutant viruses to form plaques on
parental CV-1 cells and on CV-1 cells transformed with the
selectable marker gene for neomycin resistance (CV-1 Neo)
are also shown. Confluent monolayers of each cell line were
infected and cultured under standard plaque assay condi-
tions at 37°C (32). When the maximum numbers of plaques
were visible, the cells were fixed and stained with methylene
blue for photography. Wild-type SV40 was able to form
plaques equally well on all of the cell lines. The hr/hfmutant,
however, was absolutely defective for plaque formation on
the CV-1 and CV-1 Neo cells, even at dilutions as low as
10-3. Plaques were detected on mutant-infected CV-1 Agl8
cells, indicating that the agnoprotein had a positive effect on
the plaque-forming efficiency of the mutant.
We next examined whether the expression of the agnopro-
tein in CV-1 Agl8 cells allowed the hrlhf mutants to form
plaques by increasing the levels of viral late message or
capsid protein. RNase protection analysis of total cytoplas-
mic RNA from wild-type- and mutant-infected CV-1 and
CV-1 Agl8 cells (Fig. 2) was performed as described previ-
ously (24). In this case, the probe used protects a 275-
nucleotide fragment of SV40 late mRNA from RNase diges-
tion. RNase-protected fragments were analyzed on a 6%
polyacrylamide-50% urea gel. The intensity of the 275-base
band, and therefore the amount of late mRNA, was not
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TABLE 2. Comparison of wild-type SV40, dlA2459, and dIA2475
viral yields in Vero, CV-1, and CV-1 Agl8 cells
Viral yield (PFU/cell) with:
Cell line
Wild type dlA2459 dlA2475
Vero 6,000 1,100 750
CV-1 788 3 <1
CV-1 Agl8 1,000 96 48
Jl) If).
L4r) U-
NC1"ZJ
FIG. 2. RNase protection analysis of SV40 late mRNAs. Total
cytoplasmic RNA was prepared from infected or mock-infected
cultures, and equal amounts ofRNA were annealed with 12P-labeled
anitsense RNA probe. The arrow indicates the position of the
275-nucleotide bands protected from RNase digestion by hybridiza-
tion with SV40 late mRNAs. wt, Wild type.
increased in mutant (or wild-type) infections of CV-1 Agl8
cells relative to late mRNA levels in CV-1 cells. In all of the
mutant-infected cells, the levels of late message were 5- to
10-fold lower than in wild-type-infected cells. We also
mapped the 5' ends of late viral mRNAs in mutant-infected
CV-1 Agl8 cells and found the same non-wild-type pattern
(data not shown) as reported previously for mutant-infected
CV-1 cells (24). These results indicate that the presence of
the agnoprotein had no effect on either the quantity or
structure of SV40 late mRNA. Not surprisingly, the level of
the major capsid protein, VP1, in mutant-infected CV-1
Agl8 cells was the same as in CV-1 cells, about fivefold
lower than the level observed in wild-type SV40 infections
(data not shown). We conclude that providing the agnopro-
tein in trans increased the plaque-forming efficiency of these
mutants but did not affect the accumulation of viral late
mRNA and protein.
The results of a viral yield assay comparing progeny
production by wild-type SV40 and the hr/hf mutants in Vero
cells, which were the most permissive cell line for mutant
growth; in CV-1 cells, which were the least permissive; and
in CV-1 Agl8 cells, which were able to support mutant
plaque formation, are shown in Table 2. For this assay,
multiple dishes of the three cell lines were infected with
mutant or wild-type virus. Cultures were harvested on
successive days, and maximum viral yields were determined
by plaque titration on monolayers of BSC-1 cells. These data
suggested that mutant progeny production was more efficient
in CV-1 Agl8 cells than in CV-1 cells. In this experiment,
hr/hfmutant yields were 250- to 800-fold lower than those of
the wild type in CV-1 cells but only 10- to 20-fold lower in
CV-1 Agl8 cells. For comparison, the mutant yields were
about sixfold lower than wild-type yields in Vero cells. The
infectious-center assay (Table 1) indicated that the mutant
virus yields reported in Table 2 underestimated the actual
yields of infectious mutant virus. However, it is clear from
these data that the agnoprotein, which is expressed consti-
tutively in CV-1 Agl8 cells, did not restore mutant progeny
production to wild-type levels but that it did increase mutant
virion production relative to that seen in the parental CV-1
cells.
Two factors probably account for the failure to increase
mutant progeny yields in AG18 cells to wild-type levels. (i)
The level and structure of viral late mRNAs produced in
mutant-infected AG18 cells were unchanged from those seen
in CV-1 cells. This leads to a reduction in VP1 levels in
mutant-infected CV-1 or CV-1 AG18 cells to approximately
20% of the level seen in wild-type-infected cells. The ab-
sence of the agnoprotein is a result rather that the cause of
the altered late mRNA structure. (ii) The level of agnopro-
tein synthesized in CV-1 AG18 cells was more than 100-fold
lower than that seen in wild-type-infected CV-1 cells (S.
Carswell, unpublished results). This small amount of agno-
protein may not be sufficient to maximize the yield of virions
from the available capsid protein.
We have shown previously that deletion of the carboxy
terminus of SV40 T antigen resulted in the loss of the
adenovirus helper function, altered the host range of the
mutants, and caused defects in viral late gene expression in
CV-1 cells (9, 24, 33). Among these defects in viral late gene
expression was the failure of the mutants to synthesize
detectable levels of the agnoprotein in CV-1 cells. We have
shown here that constitutive expression of the agnoprotein
in CV-1 cells allowed the hrlhf mutants to form plaques in
those cells but did not affect late mRNA or capsid protein
accumulation and did not restore progeny yields to wild-type
levels. If, as the results of the infectious center assay
suggested, there is a minimum burst size required for plaque
production, then it seems likely that providing the agnopro-
tein in trans was sufficient to boost the level of mutant virion
production above that threshold. This interpretation is con-
sistent with evidence that the agnoprotein plays a role in the
transport of capsid protein to the nucleus or in the assembly
and maturation of virions (2, 4, 23). It is also consistent with
our observation that the levels of VP1 which accumulate in
mutant-infected CV-1 cells were 5- to 10-fold lower than in
wild type-infected cells, whereas the viral yields were sev-
eral-hundred fold lower (24), suggesting inefficient produc-
tion of progeny virions from the available capsid protein
pools. We conclude from the studies described here that the
failure to produce the agnoprotein in hrlhf mutant-infected
cells is not directly responsible for the altered structure of
viral late mRNAs in mutant-infected cells but rather is an
indirect consequence of this alteration. Loss of the hrlhf
function of T antigen affects viral yields indirectly. In
mutant-infected cells, the level of viral late mRNAs is
reduced, leading to reduced production of capsid proteins;
J. VIROL.
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late mRNA structure is altered such that agnoprotein is not
produced; and finally, in the absence of agnoprotein, virion
assembly from available capsid proteins occurs with reduced
efficiency.
The carboxy-terminal 35 amino acids have been shown to
be critical for the hrlhf function (24, 33, 34). We described
previously (34) SV40 mutants in which the C terminus of
large T antigen was fused to VP1, and we demonstrated that
one of these mutants, dl(inv)2408E, was able to complement
hrlhf mutant dlA2459 for plaque formation on CV-1 cells.
This raises the question of whether the carboxy-terminal 35
amino acids of large T fused to VP1 provide hrlhf activity or
whether they complement dlA2459 by some other mecha-
nism. Studies presented here and described previously by
Stacy et al. (24) indicate that hrlhf mutations result in
production of late mRNAs at a reduced level and with 5'
ends shifted primarily to sites downstream of the agnopro-
tein AUG. We think it unlikely that the VP1-T-antigen fusion
protein of dl(inv)2408E would be able to restore mRNA
levels and structures to those seen during wild-type infec-
tion. We imagine that T antigen, through its interactions with
the SV40 origin region and with various transcription fac-
tors, affects the frequency of transcription initiation and the
location of mRNA 5' ends. Mutant T antigens lacking the
normal carboxy terminus could have altered interactions
with cellular factors, resulting in the late mRNA patterns
seen. It is difficult to imagine how the VP1-T antigen fusion
protein could play the same role in transcription initiation as
wild-type T.
How then might dl(inv)2408E act to complement dlA2459?
The studies described here provide some insight into this
problem. In the absence of detectable levels of the agnopro-
tein, dlA2459 and dlA2475 are unable to form plaques on
CV-1 monolayers (9). Providing the agnoprotein by using the
AG18 cell line permitted plaque formation to occur (Fig. 1).
Barkan et al. (2) have described missense mutations in VP1
which permit virion production to occur normally in the
absence of the agnoprotein. One interesting possibility is
that the VP1-T antigen fusion protein of dl(inv)2408E might
function in a manner similar to that of the missense mutants
in VP1 described by Barkan et al. (2); by this model, the
fusion of T-antigen sequences to VP1 might relieve the
requirement for the agnoprotein for proper transport to the
nucleus and efficient assembly into progeny virions. If this
were true, it would mean that the carboxy terminus of T
antigen could perform two distinct functions during SV40
infection: the hrlhf function when it is attached to the
remainder of T antigen, and, serendipitously, a function to
relieve the agnoprotein requirement for efficient progeny
virion formation. A major mystery which remains is how
fusions between the carboxy terminus of T antigen and
various adenovirus proteins act to permit efficient produc-
tion of human adenovirus progeny in monkey cells (31). An
understanding of the biochemical basis of the various activ-
ities of the carboxy terminus of T antigen will require further
investigation.
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